Xsolla Partners With iBLOXX to Promote Their Web3 Games Globally and Drive Launch of Upcoming Third-person Shooter Title StrayShot
iBLOXX Leverages Xsolla’s Monetization, Marketing, And Distribution Tools To Showcase Games Across MENA
Xsolla, a global video game commerce company, announces a new partnership with iBLOXX, a studio specializing in developing next-generation multiplayer games on the blockchain. The alliance was cultivated at the PGC Dubai event in April 2024, underscoring Xsolla’s continuous commitment to fostering long-term growth within the Middle East and Northern Africa region’s rapidly expanding gaming ecosystem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211854266/en/
(Graphic: Xsolla)
This strategic collaboration starts with supporting the launch of their new title, StrayShot. This thrilling third-person shooter game for PC and mobile allows players to step into the boots of a Bounty Hunter, ready to take on rivals in intense matches in several game modes. Players can team up with friends or go solo to fight other players in an epic battle for survival and earn exclusive rewards. This game is unique as it includes Web3 elements, NFTs, and tournaments, all of which Xsolla has solutions to support, particularly when it comes to subscription and virtual currency.
As a pivotal force within the MENA gaming ecosystem, Xsolla continues to leverage its advanced tools and platforms to empower partners and developers. Through this collaboration with iBLOXX, Xsolla is set to elevate the game studio’s reach and performance by providing key monetization, marketing, and distribution capabilities. Xsolla’s payments and monetization technology and expertise will ensure StrayShot gains maximum exposure while optimizing player engagement and revenue generation across multiple channels.
Chris Meredith, SVP EMEA at Xsolla, expressed his enthusiasm about the new partnership, commenting, “It’s great to work with a mature studio in the region with such a long-standing commitment to the growth and development in MENA,” he added. “This partnership will bring their groundbreaking titles and the launch of their newest title, StrayShot, to a wider audience, putting them firmly on the map as a major player in the industry.”
Domenik Maier, CEO of iBLOXX, stated: “We’re thrilled to join forces with Xsolla. Their support will be a game-changer for the upcoming launch of StrayShot, ensuring that it reaches a much larger, more engaged audience!”
The collaboration highlights Xsolla’s unwavering commitment to supporting long-term partnerships that contribute to the sustained growth and innovation of the regional gaming landscape. By partnering with iBLOXX, Xsolla is further enhancing its position in the MENA market, where gaming is experiencing rapid evolution and expansion.
For more information on Xsolla's partnership with iBLOXX to promote Web3 games globally and drive the launch of the upcoming third-person shooter StrayShot, visit xsolla.blog/xipw.
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, Montreal, and cities around the world.
For additional information and to learn more, please visit xsolla.com.
About iBLOXX
iBLOXX is a leading innovator in Web3 gaming, leveraging its extensive background in decentralized technologies and quantitative finance to craft robust, player-driven game economies and deeply engaging virtual worlds. By blending cutting-edge blockchain infrastructure with innovative design principles, iBLOXX aims to deliver richer gaming experiences — where players truly own their in-game assets and game worlds evolve in tandem with their communities.
For additional information about their upcoming title StrayShot, please visit StrayShot.game.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211854266/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom